Allianz Asset Management Gmb H Voyager Therapeutics, Inc. Transaction History

Allianz Asset Management Gmb H

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2020 Aug 14, 2020	SELL	$8.05 - $14.21 $310,746 - $548,534	-38,602 Closed	0 $0
Q1 2020 May 14, 2020	SELL	$6.8 - $14.66 $1,482 - $3,195	-218 Reduced 0.56%	38,602 $353,000
Q4 2019 Feb 13, 2020	BUY	$12.82 - $16.85 $2,205 - $2,898	172 Added 0.45%	38,820 $542,000
Q3 2019 Nov 13, 2019	SELL	$16.31 - $28.29 $901,942 - $1.56 Million	-55,300 Reduced 58.86%	38,648 $665,000
Q2 2019 Aug 08, 2019	BUY	$19.18 - $27.88 $255,842 - $371,891	13,339 Added 16.55%	93,948 $2.05 Million
Q1 2019 May 13, 2019	SELL	$8.0 - $19.66 $6,672 - $16,396	-834 Reduced 1.02%	80,609 $1.54 Million
Q4 2018 Feb 14, 2019	SELL	$8.59 - $18.05 $26,689 - $56,081	-3,107 Reduced 3.67%	81,443 $766,000
Q3 2018 Nov 13, 2018	BUY	$17.11 - $21.74 $258,395 - $328,317	15,102 Added 21.75%	84,550 $1.6 Million
Q2 2018 Aug 13, 2018	BUY	$16.76 - $23.92 $1.16 Million - $1.66 Million	69,448 New	69,448 $1.36 Million

130

34.7M

39.7K

34.6K

Ticker VYGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,647,600
Market Cap $219M
Description
Voyager Therapeutics, Inc., a gene therapy company, focuses on the development of treatments and next-generation platform technologies. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1 clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyo...

Get notified when there are updates to the investment portfolio of Allianz Asset Management Gmb H, based on Form 13F filings with the SEC.

Stay updated on Allianz Asset Management Gmb H with notifications on news.